AI Women's Health, Menopause, Fertility Fundraising (2026)

How Maven Clinic ($1.7B), Kindbody, Midi Health, Alloy, Evernow, Elektra Health, Progyny $NASDAQ:PGNY, Carrot Fertility, Stork Club, Tia.

Raising Capital for AI-Native Menopause, Perimenopause, HRT, Fertility, IVF, Egg-Freezing, PCOS, Endometriosis, Cycle-Tracking, Postpartum, Pelvic-Floor & Employer-Benefits Women's Health Startups

AI-native menopause, perimenopause, hormone-replacement-therapy-HRT, menopausal-hormone-therapy-MHT, estrogen-estradiol-transdermal, progesterone-micronized, testosterone-off-label, vaginal-estrogen, non-hormonal-fezolinetant-Veozah-Astellas-FDA-May-2023, neurokinin-3-NK3-antagonist, selective-serotonin-reuptake-inhibitor-SSRI, gabapentin, oxybutynin, cognitive-behavioral-therapy-CBT-hot-flashes, fertility, in-vitro-fertilization-IVF, intracytoplasmic-sperm-injection-ICSI, intrauterine-insemination-IUI, preimplantation-genetic-testing-PGT-A-PGT-M, egg-freezing-oocyte-cryopreservation, embryo-freezing, donor-egg, donor-sperm, surrogacy, gestational-carrier, reciprocal-IVF, third-party-reproduction, fertility-preservation-oncology, anti-Mullerian-hormone-AMH, follicle-stimulating-hormone-FSH, luteinizing-hormone-LH, estradiol-E2, progesterone-P4, polycystic-ovary-syndrome-PCOS, endometriosis, adenomyosis, uterine-fibroids, primary-ovarian-insufficiency-POI, cycle-tracking-Natural-Cycles-FDA-cleared, FemTech, postpartum-depression-Zurzuvae-zuranolone-Sage-Biogen-FDA-Aug-2023, pelvic-floor-Elvie-Perifit-Emy, lactation-consulting, midwifery, doula-services, gender-affirming-care, sexual-wellness, libido-flibanserin-Addyi, bremelanotide-Vyleesi, vulvovaginal-atrophy-VVA, genitourinary-syndrome-menopause-GSM, osteoporosis-DEXA-scan, bone-mineral-density-BMD, cardiovascular-disease-CVD-women, breast-cancer-screening, cervical-cancer-HPV, ovarian-cancer, endometrial-cancer, BRCA1-BRCA2-hereditary-risk, Tyrer-Cuzick, Gail-model, Mammaprint, Oncotype-DX, employer-benefits-fertility-family-forming is one of the highest-signal AI-consumer-health, digital-health, specialty-pharma, employer-benefits categories for 2026 — validated by Maven-Clinic $1.7B-Oct-2024-General-Catalyst-StepStone, Progyny $NASDAQ:PGNY-fertility-benefits, Carrot-Fertility $75M-Series-C-2021-Tiger-CRV, Kindbody $1.8B-2022-Perceptive, Stork-Club-Maven-2022, WIN-Fertility-Kindbody-2023, Midi-Health $60M-Series-B-Feb-2024-Emerson-GV-Google-Ventures, Alloy-Women's-Health $22M-Feb-2023, Evernow $28.5M-Feb-2022-NEA, Elektra-Health $8.5M-Aug-2023-Flare, Winona-Bonafide, Hers-Hims-Health $NYSE:HIMS-menopause-launch-Nov-2024, Amazon-One-Medical-menopause-Nov-2024, Tia $100M-Series-B-Sep-2021, Perelel $6M, Rory-Ro-menopause, Astellas-Fezolinetant-Veozah-FDA-May-2023, Sage-Biogen-Zurzuvae-zuranolone-FDA-Aug-2023-postpartum-depression, Bayer-Elinzanetant-Phase-3-2025, Ferring-Rebyota, Natural-Cycles-FDA-cleared-birth-control, Clue-BioWink, Flo-Health $200M-Series-C-2024-General-Atlantic, Oura $NYSE:OURA-cycle-tracking, Elvie $97M-Series-C-2021, Modern-Fertility-Ro-2021, Mira, Inito, Proov, LetsGetChecked $150M-Sep-2023, Everly-Health as the credible-scale AI-women's-health stack. Founders here underwrite on FDA-cleared, peer-reviewed multi-center, American-College-Obstetricians-Gynecologists-ACOG, North-American-Menopause-Society-NAMS-Menopause-Society, American-Society-Reproductive-Medicine-ASRM, Endocrine-Society, International-Menopause-Society-IMS, HIPAA, Dobbs-post-Roe-state-law, FDA-Mifepristone-Mifeprex, Human-Fertilisation-Embryology-Authority-HFEA-UK, employer-benefits-ERISA benchmark — not vanity 'AI-for-women' claims without an FDA clearance, peer-reviewed clinical validation, or credentialed OB-GYN, reproductive-endocrinologist-REI network.

Why 2026 is different

Four unlocks: (1) FDA-Astellas-Veozah-fezolinetant-May-2023 (first non-hormonal NK3-antagonist for vasomotor symptoms), Sage-Biogen-Zurzuvae-zuranolone-Aug-2023 (first oral postpartum-depression drug), Bayer-Elinzanetant-Phase-3-2025, Opill-norgestrel-OTC-Jul-2023 (first OTC oral contraceptive), FDA-Mifepristone-REMS-2023-in-person-removal proved the FDA is finally moving on women's health drug approvals after decades of stagnation — creating clean prescribing-corridor, PBM-formulary, telehealth-D2C economics for Midi-Health, Alloy, Evernow, Elektra, Hers-Hims, Winona, Amazon-One-Medical menopause launches. (2) Maven Clinic's Oct-2024 $1.7B round (General-Catalyst, StepStone, Sequoia, Icon, Oak-HC-FT), Progyny $NASDAQ:PGNY $500M+ 2024-run-rate, Carrot, Kindbody, Hers-Hims-menopause-launch-Nov-2024, Amazon-One-Medical-menopause-Nov-2024 proved fertility, menopause, family-forming as a scaled employer-benefit category (Fortune-500, self-insured-ASO, Aetna-CVS, Cigna, United-Optum, Elevance) — no longer FSA/HSA-only. (3) Post-Dobbs regulatory, privacy stack — HHS-OCR-Reproductive-Health-Privacy-Rule-Apr-2024-effective-Jun-25-2024, FTC-Health-Breach-Notification-Rule-Sep-2024, Washington-My-Health-My-Data-Act-Mar-2024, California-shield-laws, FDA-Mifepristone-SCOTUS-Jun-2024, Missouri-Amendment-3-Nov-2024, Florida-Amendment-4-Nov-2024, Alabama-IVF-embryo-personhood-Feb-2024, Kansas-Ohio-Michigan-ballot — collapsed HIPAA-BAA, state-shield, Comstock-defense into hard-gated Series-A infrastructure requirements. (4) MHPAEA-Final-Rule-Sep-2024, Pregnant-Workers-Fairness-Act-EEOC-Apr-2024, PUMP-Act-2022, Section-1557-ACA-nondiscrimination, ACA-contraceptive-post-Braidwood-Jun-2024, state-IVF-mandates-21-states, Medicaid-1115-family-planning-waiver, FSA-HSA, Family-Building-Benefit made fertility, menopause, maternal-mental-health, pelvic-floor, lactation Board-mandated benefit lines rather than optional wellness perks.

Realistic capital stack

Pre-seed / Seed $1-6M for first-cohort-clinical, first-OB-GYN-REI-network, first-HIPAA-BAA, first-state-license-DEA-registration, first-PBM-contract, first-D2C-telehealth-launch (Elektra $8.5M-Aug-2023, Perelel $6M, Rosy-Wellness, Coral, Ferly, Kegg, Proov, Inito, Mira-early, Emme, Bloomi). Series A/B $20-100M for FDA-clearance, multi-state-license, PBM-formulary-Express-Scripts-CVS-Caremark-OptumRx, peer-reviewed multi-center, Fortune-500-employer-contract, Aetna-CVS-Cigna-United-Elevance-BCBS-in-network, Livongo-Teladoc-model scale (Midi-Health $60M-B-Feb-2024-Emerson-GV, Alloy $22M-Feb-2023, Evernow $28.5M-Feb-2022-NEA, Alife-Health $22M-Bessemer, Elvie $97M-C-2021, Flo-Health $200M-C-2024-General-Atlantic, LetsGetChecked $150M-Sep-2023, Carrot $75M-C-2021-Tiger-CRV). Growth, IPO, PE, strategic $200M-$2B+ — Maven-Clinic $1.7B-Oct-2024-General-Catalyst-StepStone-Sequoia-Icon-Oak-HC-FT, Kindbody $1.8B-2022-Perceptive, Progyny $NASDAQ:PGNY-IPO-Oct-2019, Hers-Hims $NYSE:HIMS-menopause-Nov-2024, Ro-Modern-Fertility-2021, Amazon-One-Medical-menopause-Nov-2024, Labcorp-Ovia-2021, Merck-Organon-spinoff-2021, Astellas-Iveric-$5.9B-2023-adj, Sage-Biogen-Zurzuvae, Bayer-Elinzanetant, Pfizer-Duavee. Non-dilutive material — NIH-ORWH-Office-Research-Womens-Health, Eunice-Kennedy-Shriver-NICHD, ARPA-H-Sprint-for-Women's-Health-Feb-2024, Bill-Melinda-Gates-Foundation, Milken-FasterCures, Susan-G-Komen, NAMS-research-grant, ASRM-research.

Common failure modes

Overclaiming pregnancy-rate, live-birth-rate, euploidy-rate, hot-flash-reduction, AMH-response, hormone-optimization, libido-restoration, postpartum-depression-response without FDA-clearance, peer-reviewed multi-center Obstetrics-Gynecology, Fertility-Sterility, Human-Reproduction, Menopause-NAMS, JAMA, NEJM, Lancet, BMJ, ACOG-Committee-Opinion, NAMS-2022-Position-Statement, ASRM, Endocrine-Society, SMFM validation, HIPAA-BAA, HHS-OCR-Reproductive-Health-Privacy-Rule-Apr-2024, FTC-Health-Breach-Notification-Sep-2024, Washington-My-Health-My-Data, California-CCPA-CPRA compliance — post-Maven-Clinic-$1.7B-Oct-2024, Astellas-Veozah-May-2023, Sage-Zurzuvae-Aug-2023, Bayer-Elinzanetant-2025, Opill-Jul-2023, Dobbs-Jun-2022, HHS-OCR-Rule-Jun-2024, FTC-Cerebral-BetterHelp-GoodRx-Flo-Health-enforcement, Alabama-IVF-personhood-Feb-2024 credible-scale bar, operators without FDA, peer-reviewed, ACOG/NAMS/ASRM, HIPAA, state-license, shield-law, PBM-formulary, Fortune-500-employer, Aetna-CVS-Cigna-United-Elevance-BCBS-in-network audit trail get flagged by General-Catalyst, StepStone, Sequoia, Icon, Oak-HC-FT, Perceptive, Tiger, CRV, NEA, Emerson, GV-Google-Ventures, Flare-Capital, General-Atlantic, Bessemer, Redesign-Health diligence within 12-18 months. Underestimating Dobbs-Comstock-state-shield legal risk — Texas-Paxton-New-York-Dr-Carpenter-Dec-2024, Louisiana-mifepristone, Missouri-Kansas-abortion-shield, interstate-liability, telemedicine-abortion-Aid-Access-Plan-C, Alabama-IVF-embryo-personhood-Feb-2024, LePage-v-Center-for-Reproductive-Medicine — creates D&O, malpractice, criminal-liability, investor-reputational risk unmatched in other healthcare verticals. Building yet-another D2C-HRT-telehealth or fertility-benefits or cycle-tracker in a market where Maven-Clinic, Progyny, Carrot, Kindbody, Midi, Alloy, Hers-Hims, Amazon-One-Medical, Flo-Health, Clue, Oura, Modern-Fertility-Ro already have deep employer, PBM, retail-pharmacy integration, without a defensible FDA-cleared, ACOG/NAMS/ASRM-guideline, shield-law-compliant, Fortune-500-employer-anchored wedge.

Frequently asked questions

Is there room for another AI-native women's health, menopause or fertility startup vs. Maven-Clinic $1.7B, Progyny, Carrot, Kindbody, Midi, Alloy, Hers-Hims, Amazon-One-Medical, Flo-Health, Astellas-Veozah, Sage-Biogen-Zurzuvae?
Yes, at the condition, hormone, life-stage, channel, geography where incumbents don't have depth. Defensible wedges are (a) condition (perimenopause, menopause, PCOS, endometriosis, adenomyosis, uterine-fibroids, primary-ovarian-insufficiency-POI, vulvovaginal-atrophy, genitourinary-syndrome-menopause, osteoporosis, hypoactive-sexual-desire-disorder-HSDD, hyperemesis-gravidarum, hypertensive-disorders-pregnancy, preeclampsia, gestational-diabetes, postpartum-depression, postpartum-hemorrhage, pelvic-organ-prolapse, urinary-incontinence, interstitial-cystitis, vulvodynia, lichen-sclerosus, pediatric-adolescent-gynecology, gender-affirming-care), (b) hormone, drug (estradiol-transdermal, oral, vaginal, progesterone-micronized, testosterone-off-label, fezolinetant-NK3, elinzanetant, zuranolone, flibanserin, bremelanotide, hyaluronic-acid, ospemifene-Osphena, prasterone-Intrarosa, tibolone, selective-estrogen-receptor-modulator-SERM, Duavee-bazedoxifene-conjugated-estrogens), (c) life-stage (adolescent, reproductive-age, preconception, fertility, pregnancy, postpartum, perimenopause, menopause, postmenopause, elderly), (d) channel (D2C-telehealth, employer-benefits-carve-out, PBM-Express-Scripts-CVS-OptumRx, retail-pharmacy-CVS-Walgreens-Walmart, Amazon-Pharmacy, Medicaid-managed-care, Medicare-Advantage, FQHC-Federally-Qualified-Health-Center, Title-X, hospital-OB-GYN, REI-fertility-clinic, midwife-birth-center, doula, home-birth), (e) geography (US-Dobbs-shield-vs-ban-state, Canada, UK-NICE-NHS, EU-CTR, Australia-TGA, Brazil-ANVISA, Mexico, India, South-Africa, LatAm).
How do investors underwrite an AI-Native Women's Health startup post-Dobbs?
Best-in-class disclosures beat headline user, revenue claims: FDA-510(k)-PMA-De-Novo-SaMD-PCCP-Aug-2024 clearance benchmark, FDA-drug-approval (Veozah, Zurzuvae, Elinzanetant, Opill, Addyi, Vyleesi, Duavee, Mifepristone) benchmark, peer-reviewed clinical validation live-birth-rate, cumulative-live-birth, euploidy-rate, implantation, clinical-pregnancy, oocyte-yield, AMH, FSH, E2, hot-flash-frequency-VMS, Menopause-Rating-Scale, Greene-Climacteric, MENQOL, EPDS, PHQ-9 published in Obstetrics-Gynecology, AJOG, Fertility-Sterility, Human-Reproduction, Menopause-NAMS-Journal, JAMA, NEJM, Lancet, BMJ multi-center, ACOG, NAMS-2022-Position-Statement, IMS, ASRM, Endocrine-Society, SMFM, AWHONN compliance, HIPAA, HITRUST, SOC-2, HHS-OCR-Reproductive-Health-Privacy-Rule-Apr-2024-Jun-25-2024, FTC-Health-Breach-Notification-Sep-2024, Washington-My-Health-My-Data, California-CCPA-CPRA, Illinois-BIPA, GDPR-Article-9 compliance, Dobbs-shield-law-California-NY-Mass-WA, Comstock-defense, FDA-Mifepristone-SCOTUS-Jun-2024, Missouri-Amendment-3-Florida-Amendment-4-Alabama-IVF-personhood posture, ERISA, MHPAEA-Final-Rule-Sep-2024, Pregnant-Workers-Fairness-Act-EEOC-Apr-2024, PUMP-Act, Section-1557-ACA, ACA-contraceptive-Braidwood, 21-state-IVF-mandate, Medicaid-1115 benchmark, HFEA-UK, NICE-NG23, EU-CTR, FIGO compliance, employer-benefits book-of-business Fortune-500, Aetna-CVS, Cigna, United-Optum, Elevance-Anthem, BCBS, Kaiser, PBM-Express-Scripts-CVS-Caremark-OptumRx contract benchmark.
Which investors write AI-Native Women's Health, Menopause, Fertility checks?
FemTech, digital-health, consumer-health specialists: General Catalyst (Maven-Clinic-$1.7B-Oct-2024 lead, Livongo, Ro, Mindstrong), Sequoia (Maven, Carrot-adj, Flo-adj, Alife-adj), Icon Ventures (Maven-lead), Oak HC/FT (Maven, Kindbody, Everly-Health, Hazel-Health), StepStone (Maven-Oct-2024), Perceptive Advisors (Kindbody-$1.8B-2022, Ambrx), Tiger Global (Carrot $75M-C-2021), CRV (Carrot), NEA (Evernow $28.5M-Feb-2022), Emerson Collective (Midi-Health-$60M-B-Feb-2024 lead), GV-Google Ventures (Midi, Elektra, Flo-adj), Flare Capital (Elektra $8.5M-Aug-2023), General Atlantic (Flo-Health $200M-C-2024, Progyny-pre-IPO), Bessemer (Alife, Alto), Deena Shakir-Lux (Alife, Everlywell, Ambulnz), a16z Bio (Rockit, Modern-Fertility-adj), 8VC (Cityblock, Alto, Rockit), F-Prime (Alto, Everlywell, Hinge-adj), Ribbit (Rockit, Ro-adj), Redesign Health (Jasper-Health, Elektra-incubated). Growth, strategic — Progyny $NASDAQ:PGNY, Hers-Hims $NYSE:HIMS, Ro-Roman, LetsGetChecked $150M-Sep-2023, Everly-Health, Amazon-One-Medical, Elevance-Anthem, Aetna-CVS, Cigna, United-Optum-Rally, Astellas-Veozah, Bayer-Elinzanetant, Organon-Merck-2021, Sage-Biogen-Zurzuvae, Pfizer-Duavee, Ferring, Merus-KG, Theramex, Mithra-Estelle, Materna-Medical.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database